Drug Class: Immunotherapy

Checkpoint Inhibitors: CD47

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Prior Therapies Not Reported

Checkpoint Inhibitors: CTLA-4

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Prior Therapies Not Reported

Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Prior Therapies Not Reported

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Prior Therapies Not Reported

Checkpoint Inhibitors: PD-1

Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

1 Prior Therapy Prior Therapies Not Reported

Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Prior Therapies Not Reported

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

2 Prior Therapies 3 Prior Therapies 4 Prior Therapies 5 Prior Therapies Prior Therapies Not Reported

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

2 Prior Therapies

Checkpoint Inhibitors: PD-L1

Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

First-line treatment with/without extended (maintenance) treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

1 Prior Therapy 2 Prior Therapies

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

2 Prior Therapies 3 Prior Therapies Prior Therapies Not Reported

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

3.5 Prior Therapies Prior Therapies Not Reported

Checkpoint Inhibitors: CD47

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT03558139 Ib Avelumab, Magrolimab A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy

Magrolimab+avelumab is a novel, well-tolerated combination with a 56% stable disease rate in ovarian cancer patients

DCR: 56% (10SD)

abs Feb 2020

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02216409 I Magrolimab A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies

Promising activity with manageable toxicity in CC and FT OvCa

ORR: 15.4% (n=13)

Pub 2019

Checkpoint Inhibitors: CTLA-4

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT01611558 II Ipilimumab A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects

Ipilimumab shows encouraging anti-tumor activity, but with serious side effects

ORR: 10.3%

pub 2017

Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02498600 II Ipilimumab, Nivolumab Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Encouraging anti-tumor activity of ipilimumab+nivolumab combination with favorable benefit over risk

Ipi+Niv vs Niv:
ORR: 31.4 vs 12.2%*
PFS: 3.9 vs 2.0 months*

pub 2020

*Statistically significant result

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT01975831 I Durvalumab, Tremelimumab A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Tremelimumab+durvalumab has a manageable safety profile with preliminary evidence of clinical activity in ovarian cancer

ORR: 7.4%
DCR: 44.4%

abs May 2017

Checkpoint Inhibitors: PD-1

Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT03245892 I Carboplatin, Nivolumab, Paclitaxel A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

In high-risk ovarian cancer patients, addition of nivolumab to neoadjuvant chemotherapy and as maintenance shows promising PFS and favorable changes in the tumor microenvironment

20 patients
90% achieved optimal cytoreducation at interval surgery (70% R0, 20% R1)
PFS: 15 months
PFS (12 months): 69.6%
Treatment associated w/ significant increase in CD8+ T cells (P = 0.0002)

abs Mar 2020

First-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02766582 II Carboplatin, Paclitaxel, Pembrolizumab Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising

28 patients
PFS (6 months): 82%
PFS (9 months): 77%
PFS (12 months): 59%

abs Mar 2020

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02873962 II Bevacizumab, Nivolumab A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Encouraging activity of nivolumab+bevacizumab combination

ORR: 40%
CBR: 70%
PFS: 12.1 months

pub 2019

NCT02660034 I/Ib Pamiparib, Tislelizumab A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Tislelizumab+pamiparib is well tolerated and associated with antitumor responses in both BRCA WT and BRCA MUT ovarian cancer

16 evaluable Pt-S:
ORR: 44%
DCR: 63%

pub 2019

Partially Pt-Sensitive/Resistant: Treatment given for recurrence occurring 6-12 months or less than 6 months after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02498600 II Ipilimumab, Nivolumab Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Encouraging anti-tumor activity of ipilimumab+nivolumab combination with favorable benefit over risk

Ipi+Niv vs Niv:
ORR: 31.4 vs 12.2%*
PFS: 3.9 vs 2.0 months*

pub 2020

*Statistically significant result

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
JapicCTI-153004; NINJA III Gemcitabine, Liposomal doxorubicin, Nivolumab Multicenter, open-label, randomized study in patients with ovarian cancer(ONO-4538-23)

Nivolumab does not improve OS compared with gemcitabine/liposomal doxorubicin in patients with platinum resistant ovarian cancer

PFS: 2.0 vs 3.8 months
OS: 10.1 vs 12.1 months

pub 2021

NCT02440425 II Paclitaxel, Pembrolizumab Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer

Pembrolizumab+paclitaxel shows improved ORR and PFS compared to historical results with paclitaxel

ORR: 51.4%
PFS: 6.7 months
OS: 13.4 months

Press release Feb 2020

NCT02608684 II Cisplatin, Gemcitabine, Pembrolizumab A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

Adding pembrolizumab to cisplatin+gemcitabine and continuing as single-agent maintenance treatment results in promising response rates

ORR: 61.1%
PFS: 6.2 months

pub 2021

NCT02853318 II Bevacizumab, Cyclophosphamide, Pembrolizumab A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Pembrolizumab+bevacizumab+cyclophosphamide is well tolerated and demonstrates clinical benefit and durable treatment responses

ORR: 43.3%
DCR: 95%
PFS: 7.6 months

pub 2020

NCT02865811 II Liposomal doxorubicin, Pembrolizumab A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Encouraging anti-tumor activity of pembrolizumab+liposomal doxorubicin with acceptable safety profile

ORR: 26.1%
CBR: 52.2%

pub 2020

NCT02873962 II Bevacizumab, Nivolumab A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Nivolumab+bevacizumab shows activity in Pt-R patients, independent of PD-L1 expression

ORR: 16.7%
CBR: 33.3%
PFS: 7.7 months

pub 2019

NCT02901899 II Guadecitabine, Pembrolizumab An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

Pembrolizumab+guadecitabine has modest activity but some patients experience prolonged disease stabilization

ORR: 9.1%
DCR: 54.5%
PFS: 2.8 months

abs May 2020 and poster

NCT03574779; OPAL II Bevacizumab, Niraparib, Dostarlimab Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer

Triplet therapy with dostarlimab, niraparib, and bevacizumab is tolerable and demonstrates clinical activity in patients with BRCA WT platinum resistant ovarian cancer without HRR gene mutations

ORR: 17.9%
DCR: 76.9%
PFS: 7.6 months

w/ prior Bev: ORR: 6%
w/o prior Bev: ORR: 27%

abs Mar 2021

NCT03797326 II Pembrolizumab, Lenvatinib A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

Pembrolizumab+lenvatinib demonstrates encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure

ORR: 24%

abs Sep 2020

UMIN000005714 II Nivolumab A Phase II trial of immunotherapy with an anti-PD-1 antibody in advanced / relapsed, Platinum - resistant Ovarian Cancer

Encouraging anti-tumor activity of single-agent nivolumab with acceptable safety profile

ORR: 15%
DCR: 45%
PFS: 3.5 months

pub 2015

NCT02606305; FORWARD II Ib/II Pembrolizumab, Mirvetuximab soravtansine A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Encouraging activity of pembrolizumab+mirvetuximab soravtansine combination in FRalpha+ patients

ORR: 30%
PFS: 4.2 months

abs Mar 2018; Oct 2018

NCT02657889; TOPACIO I/II Niraparib, Pembrolizumab Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer (TOPACIO)

Promising activity of niraparib+pembrolizumab in platinum resistant patients independent of BRCA status, HRD status and PD-L1 expression

ORR: 21%

pub 2019

NCT03029598 I/II Carboplatin, Pembrolizumab Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Pembrolizumab+carboplatin is well-tolerated and active in recurrent platinum-resistant ovarian cancer. A ratio of peripheral T-cell exhaustion to radiographic tumor burden may identify patients more likely to benefit from this chemoimmunotherapy

ORR: 10.3%; DCR: 63%
PFS: 4.6 months
All 7 PD-L1+ patients achieved PR or SD

pub 2021

NCT02660034 I/Ib Pamiparib, Tislelizumab A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Tislelizumab+pamiparib is well tolerated and associated with antitumor responses in both BRCA WT and BRCA MUT ovarian cancer

18 evaluable Pt-R:
ORR: 22%
DCR: 50%

pub 2019

NCT02054806; KEYNOTE-028 I Pembrolizumab Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Pembrolizumab shows encouraging anti-tumor activity with acceptable safety profile

ORR:12%
DCR: 35%
PFS: 1.9 months

pub 2019

NCT03596281; PEMBOV I Bevacizumab, Liposomal doxorubicin, Pembrolizumab An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer

Bevacizumab+liposomal doxorubicin+pembrolizumab is well tolerated and demonstrate durable responses in platinum resistant ovarian cancer patients

Bev+Pem:
ORR: 26.3%
DCr: 78.9%

Bev+PLD+Pem:
ORR: 32%
DCR: 74%
CBR: 53%

abs Jun 2021 and poster, abs Nov 2021

NCT03666143 I Tislelizumab, Sitravatinib A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Combination treatment with sitravatinib and tislelizumab is manageable and shows promising anti-tumor activity

ORR: 26%
PFS: 4.1 months

abs Apr 2021 and presentation

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02598960 IIa BMS-986156, Nivolumab A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors

Nivolumab+BMS-986156 is safe and has efficacy comparable to historical data reported for nivolumab monotherapy

ORR: 2.7%
DCR: 51.4%

pub 2019

NCT02178722 II Epacadostat, Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)

Pembrolizumab and epacadostat combination shows encouraging anti-tumor activity with acceptable safety

ORR: 8%
DCR: 35%

abs Jun 2017

NCT02674061; KEYNOTE-100 II Pembrolizumab A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)

Modest anti-tumor activity of single-agent pembrolizumab with acceptable safety profile

ORR: 8.5%
CBR: 22.1%

pub 2019, abs May 2020 and presentation

Checkpoint Inhibitors: PD-L1

Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02726997 I/II Carboplatin, Durvalumab, Paclitaxel Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Durvalumab with chemotherapy in upfront ovarian cancer and continued as maintenance is safe and shows reasonable efficacy

83% obtained optimal cytoreduction at surgery
PFS: 14.5 months

abs Apr 2020

First-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02718417; JAVELIN Ovarian 100 III Avelumab, Carboplatin, Paclitaxel A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (MSB0010718C) In Combination With And/Or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100

Avelumab addition to carboplatin+paclitaxel and/or continued as maintenance therapy for newly diagnosed ovarian cancer patients does not improve PFS; PD-L1, CD8, and gBRCA1/2 status did not predict differential clinical benefit 

CarboPt+Pac+Ave+Ave maint vs CarboPt+Pac+Ave maint vs CarboPt+Pac:

ORR: 36.0 vs 30.4 vs 30.4%
PFS: 18.1 vs 16.8 vs NR months

pub 2021

NCT03038100; IMagyn050 III Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Atezolizumab does not significantly improve PFS in the ITT or PD-L1+ population. The combination is generally well tolerated with manageable AEs; neither BRCA MUT nor HRD+ was associated with greater clinical benefit from adding atezolizumab

CarboPt+Tax+Bev+Ate vs CarboPt+Tax+Bev+Placebo:
PFS: 19.5 vs 18.4 months

PD-L1+ patients:
PFS: 20.8 vs 18.5 months

pub 2021

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02734004; MEDIOLA I/II Bevacizumab, Durvalumab, Olaparib A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

Promising activity of durvalumab+olaparib in gBRCA MUT ovarian cancer patients; durvalumab+olaparib+bevacizumab shows promising activity in non-gBRCA MUT patients regardless of LOH score and mutation status of common DDR genes

Dur+Ola, gBRCA MUT:
ORR: 71.9%
DCR (7 months): 65.6%
PFS: 11.1 months

Dur+Ola, non-gBRCA MUT:
ORR: 34%
CBR: 28%
PFS: 5.5 months

Dur+Ola+Bev, non-gBRCA MUT:
ORR: 87%
CBR: 77%
PFS: 14.7 months

abs Oct 2019, abs Sep 2020, pub 2020

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT03699449 II Durvalumab, Olaparib An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Durvalumab+olaparib shows promising activity in BRCA MUT patients

ORR: 35.7%

abs Jun 2021 and poster

NCT02580058; JAVELIN Ovarian 200 III Avelumab, Liposomal doxorubicin A Phase 3, Multicenter, Randomized, Open-Label Study Of Avelumab (MSB0010718C) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-Resistant/Refractory Ovarian Cancer

No significant improvement in ORR, PFS or OS with avelumab+liposomal doxorubicin (PLD) compared to avelumab or PLD alone

Ave+PLD vs Ave vs PLD:

ORR: 13.3 vs 3.7 vs 4.2%
PFS: 3.7 vs 1.9 vs 3.5 months
OS: 15.7 vs 11.8 vs 13.1 months

pub 2021

NCT02431559 II Durvalumab, Liposomal doxorubicin Phase 1/2 Study of Chemoimmunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) + Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin is Indicated

Durvalumab+liposomal doxorubicin has a tolerable safety profile and promising efficacy

ORR: 22.5%
PFS: 5.5 months
OS: 17.6 months

abs Mar 2020

NCT02659384; EORTC-1508 II Acetylsalicylic acid, Atezolizumab, Bevacizumab A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

The addition of atezolizumab to bevacizumab (with or without acetylsalicylic acid) improves PFS and TFST

Bev vs Bev+Ate vs Bev+Ate+Asa:

ORR: 24.1 vs 20.7 vs 27.6%
PFS: 2.3 vs 4.1 vs 4.0 months
TFST: 3.0 vs 5.3* vs 5.8 months*

abs Sep 2021

NCT01633970 Ib Atezolizumab, Bevacizumab A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors

Atezolizumab+bevacizumab induces durable responses and/or disease stabilization in some patients with platinum-resistant ovarian cancer; the safety profiles are consistent with those of each agent

ORR: 15%
PFS: 4.9 months
OS: 10.2 months

pub 2020

NCT01772004 I Avelumab A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Avelumab shows encouraging activity with acceptable safety profile in ovarian cancer

ORR: 9.6%
DCR: 52.0%
PFS: 2.6 months

pub 2019

*Statistically significant result

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02484404 I/II Durvalumab, Olaparib, Cediranib Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

Promising response rates for durvalumab, cediranib and olaparib in ovarian cancer

Dur+Ola: 34 evaluable:
ORR: 15%
DCR (4 months): 53%

Dur+Ced: 7 evaluable:
ORR: 42.9%
DCR (4 months): 71.4%

Dur+Ola+Ced: 7 evaluable:
ORR: 42.9%
DCR: 71.4%
most patients Pt-R, BRCA WT

pub 2017; abs Oct 2018, pub 2019

NCT01375842 I Atezolizumab A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Atezolizumab shows encouraging activity with acceptable safety profile in PD-L1+ patients

9 evaluable ovarian:
ORR: 22%

pub 2019

NCT01975831 I Durvalumab, Tremelimumab A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Durvalumab+tremelimumab has a manageable safety profile with preliminary evidence of clinical activity in ovarian cancer

ORR: 7.4%
DCR: 44.4%

abs May 2017

< Return to Drug Classes

< Return to Clinical Trial Results Homepage